Eszopiclone, sold under the brand name Lunesta, is a prescription sedative hypnotic used short term for sleep. People who take it and are facing an employment, probation, or clinical drug screen often ask a direct question: will eszopiclone show up on a drug test, and will it get flagged as a benzodiazepine. The honest answer is that it depends entirely on what the test is built to detect, and a standard workplace benzodiazepine immunoassay is generally not built to detect it.
This article explains how eszopiclone is classified, why it is grouped with other Z drugs like zolpidem and zaleplon, why the common BZO screening panel does not reliably pick it up, and what happens when a lab needs to confirm it specifically. It is written for employers, screening program administrators, and people who have been prescribed eszopiclone and want to understand the testing process, not to help anyone evade a test.
Eszopiclone is a Z drug, not a benzodiazepine
Eszopiclone belongs to a group of sedative hypnotics informally called Z drugs because their generic names start with that letter: eszopiclone, zolpidem, and zaleplon. Despite sharing a drug class nickname and a similar clinical use, the three are chemically distinct from one another and from benzodiazepines.
According to the current prescribing information on DailyMed, eszopiclone is a cyclopyrrolone and is listed as a Schedule IV controlled substance under the Controlled Substances Act. The label states plainly that eszopiclone has a chemical structure unrelated to benzodiazepines, even though it shares some pharmacologic properties with them because both act at the GABA receptor complex. That single sentence is the reason this question comes up so often: eszopiclone behaves somewhat like a benzodiazepine in the body, but it is not one on paper, and a test built to find benzodiazepine metabolites is not built to find it.
The MedlinePlus drug information page on eszopiclone, published by the National Library of Medicine, describes it as a sedative used to help people fall asleep and stay asleep, and it reinforces that eszopiclone works on the central nervous system in a way that overlaps with, but is not identical to, benzodiazepine sedatives.
Why the standard BZO immunoassay does not reliably catch Z drugs
Most employer and clinical urine drug screens use an immunoassay, a rapid test that relies on antibodies built to recognize the chemical shape of a specific target molecule or a close family of related molecules. The benzodiazepine immunoassay, usually labeled BZO on a test cup or dip card, is designed around the chemical backbone shared by true benzodiazepines such as diazepam, alprazolam, lorazepam, and their shared metabolites like oxazepam and nordiazepam.
Eszopiclone, zolpidem, and zaleplon do not share that backbone. Eszopiclone is a cyclopyrrolone, zolpidem is an imidazopyridine, and zaleplon is a pyrazolopyrimidine. The DailyMed label for zaleplon states directly that it has a chemical structure unrelated to benzodiazepines, barbiturates, or other hypnotics, even though it interacts with the same GABA benzodiazepine receptor complex. The DailyMed label for zolpidem similarly identifies it as a nonbenzodiazepine hypnotic of the imidazopyridine class. Because an antibody based immunoassay recognizes shape, a molecule that does not resemble the benzodiazepine backbone generally will not bind well to a BZO antibody, so eszopiclone, zolpidem, and zaleplon typically do not trigger a positive BZO result at standard screening cutoffs. Published cross reactivity evidence specific to eszopiclone on BZO immunoassays is limited, and the safest statement for a program to make is that there is no credible, well documented cross reactivity between eszopiclone and the standard BZO panel, not that a negative result is promised in every case or with every manufacturer's assay.
This also means eszopiclone will not show up as an opiate, amphetamine, THC, or cocaine positive. It is a sedative hypnotic, not a member of any of those drug classes, and a standard multi panel cup has no target built to catch it unless that specific analyte is added to the panel.
When a lab tests for Z drugs specifically
Because the common panels miss Z drugs, a workplace or clinical program that has a real reason to monitor for eszopiclone, zolpidem, or zaleplon use needs to order an expanded panel or a specific confirmation test rather than relying on the BZO screen. Reference and forensic toxicology laboratories can run liquid chromatography tandem mass spectrometry, often written as LC-MS/MS, to identify eszopiclone and its metabolites directly, the same confirmation technology used to verify any presumptive immunoassay result. Some expanded urine or blood panels marketed for pain management or impaired driving investigations add zolpidem or a broader sedative hypnotic analyte list, but a generic workplace drug test cup almost never includes a dedicated Z drug target.
Anyone who is prescribed eszopiclone and is concerned about a test result should give the collector or the medical review officer the prescription information at or before the collection, and should never be asked and should never be told to try to adjust a specimen or a dose to influence a result. That decision belongs to the prescribing clinician and the patient, never to a testing program.
The medical review officer process still applies
If a laboratory flags any result for review, a certifying scientist and a medical review officer evaluate it against the person's reported medications before a final result is reported to an employer. A positive benzodiazepine or sedative related finding, where the panel actually includes that analyte, is handled the same way any other prescription related finding is handled: the medical review officer contacts the individual, reviews valid prescription documentation, and determines whether the result is consistent with legitimate medical use before it is reported as verified. This review process is a safeguard, not a loophole, and it applies regardless of which specific sedative is involved.
Eszopiclone, zolpidem, zaleplon, and temazepam compared
| Medication | Drug class | Controlled substance schedule | Detected by standard BZO panel | How it is confirmed when relevant |
|---|---|---|---|---|
| Eszopiclone (Lunesta) | Cyclopyrrolone, Z drug | Schedule IV | No, not reliably at standard cutoffs | LC-MS/MS targeting eszopiclone specifically |
| Zolpidem (Ambien) | Imidazopyridine, Z drug | Schedule IV | No, not reliably at standard cutoffs | LC-MS/MS targeting zolpidem specifically |
| Zaleplon (Sonata) | Pyrazolopyrimidine, Z drug | Schedule IV | No, not reliably at standard cutoffs | LC-MS/MS targeting zaleplon specifically |
| Temazepam (Restoril) | True benzodiazepine | Schedule IV | Yes, this is the chemical class the BZO panel targets | LC-MS/MS confirmation of the benzodiazepine screen |
The DailyMed label for temazepam confirms it is a Schedule IV controlled substance and a true benzodiazepine, which is exactly the chemical family the BZO immunoassay is built to find. The contrast is useful: temazepam belongs to the class the panel targets, while eszopiclone, zolpidem, and zaleplon share a nickname and a controlled substance schedule with benzodiazepines but not the chemical backbone a BZO antibody recognizes.
What this means for an employer or screening program
A program that wants to monitor Z drug use for safety sensitive roles, such as positions involving heavy machinery or night shift fatigue concerns, should not assume a standard panel covers it. Build the panel deliberately: decide whether sedative hypnotics are a real risk for the role, confirm with the lab which analytes an expanded panel actually includes, and route every non negative result through standard medical review officer verification with prescription documentation rather than treating a flagged result as automatic cause for action. American Screening Corporation supplies drug test cups, dip cards, and oral fluid tests across a range of panel configurations; employers who need an expanded or custom panel should review the drug test cup collection and ask which analytes a given panel configuration covers before assuming a sedative or Z drug is included.
For background on how the benzodiazepine panel itself works and where its detection gaps lie, see this related article on the benzodiazepine drug test BZO panel. For a closer look at zolpidem specifically, the companion post on whether Ambien shows up on a drug test walks through the same Z drug detection question for that medication.
Frequently asked questions
Does eszopiclone show up on a standard 5 panel or 10 panel drug test?
No. Standard multi panel cups screen for drug classes like marijuana, cocaine, opiates, amphetamines, and PCP, and many also include a BZO benzodiazepine target. Eszopiclone is chemically unrelated to benzodiazepines, so it is not reliably detected by any of the standard immunoassay targets found on a typical panel.
Will eszopiclone trigger a positive benzodiazepine result?
There is no credible, well documented cross reactivity showing that eszopiclone reliably triggers a positive BZO immunoassay result at standard cutoffs. The chemical structure is different from true benzodiazepines, which is what the BZO antibody is designed to recognize.
Is eszopiclone a controlled substance?
Yes. According to the DailyMed prescribing information, eszopiclone is a Schedule IV controlled substance under the Controlled Substances Act, the same schedule as many benzodiazepines, even though it is a different chemical class.
Can a lab test specifically for eszopiclone, zolpidem, or zaleplon?
Yes. A reference laboratory can run a targeted confirmation test, typically liquid chromatography tandem mass spectrometry, to identify these Z drugs and their metabolites directly. This is not part of a routine workplace panel and has to be ordered as an expanded or specific test.
What should someone prescribed eszopiclone do before a drug test?
Bring current prescription documentation to the collection site and be prepared to discuss it with the medical review officer if any result is flagged for review. Never attempt to adjust a dose or a specimen to influence a test result, since that decision belongs with the prescribing clinician.
Does a positive sedative related result automatically mean a failed test?
No. Any non negative laboratory result goes through confirmation testing and medical review officer evaluation, where valid prescription documentation is considered before a final result is reported to an employer.
This article is general information about drug testing science and procedure, not medical or legal advice. Anyone with questions about a specific medication, dose, or test result should consult a licensed clinician or a medical review officer.
